All In Biotech

Drug Trial Radar · NCT07777120

Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma

Non-interventional Cohort Study of Patients Treated With Liso-Cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Marginal Zone Lymphoma in the Postmarketing Setting

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Mar 24, 2026

Primary completion

Mar 31, 2048

Study completion Mar 31, 2048

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This non-interventional study will use information already reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry during routine clinical care. The study will assess the long-term safety and effectiveness of lisocabtagene maraleucel in participants with relapsed/refractory marginal zone lymphoma.

Conditions

  • Marginal Zone Lymphoma

Interventions

  • lisocabtagene maraleucelBiological

    As per United States prescribing information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of selected adverse events after lisocabtagene maraleucel infusionTime frame: Up to 15 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for International Blood and Marrow Transplant Research (CIBMTR)

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.